Scientists have pinpointed likely “cells of origin”, the source cells that can grow into breast cancer, in women carrying a faulty BRCA2 gene who are at high risk of developing …
Endocrine resistance – a major cause of breast cancer deaths – can be underpinned by an epigenetic change called DNA methylation.
Technological advancements have enabled scientists to explore genetic control elements, unravelling the complexities of gene activation mechanisms in our genetic code.
A new study has revealed that a molecule found in human milk and animal products such as meat and dairy can infiltrate tumours and kill cancer cells.
Blood cells reveal tumours in the body. Researchers achieve an advance with the development of a test for early diagnosis of cancer.
Pancreatic cancer is one of the deadliest cancers; only about 1 in 8 patients survives five years after diagnosis.
Pancreatic cancer is tricky to manage because it spreads easily and early, and the tumours have a unique biological makeup.
Pancreatic cancers are among the most aggressive, deadly tumous and, for years, researchers have struggled to develop effective drugs against them.
A new cancer therapy attacks tumours by tricking cancer cells into absorbing a snippet of RNA that naturally blocks cell division.
A new study highlights the potential of artificial DNA structures that, when fitted with antibodies, instruct the immune system to specifically target cancerous cells.
A new approach developed by researchers at MIT and Dana-Farber Cancer Institute may make it easier to identify the sites of origin for enigmatic cancers.
Examining enzyme MAPK4, researchers have now identified a strategy that can potentially control MAPK4-promoted growth in triple negative breast cancer and other cancers.
For people with cancer, chemotherapy saves lives, but for some patients, the treatment comes with a side effect: heart damage.
- Health & Wellness
ICB therapy, which stands for immune checkpoint blockade, has become the standard treatment for lung cancer due to its generally positive outcomes.
A new nuclear medicine therapy can cure human non-Hodgkin lymphoma in an animal model.